Abstract
The primary and patent literature (July 1993 to February 1995) describing angiotensin II antagonists, renin inhibitors, angiotensin converting enzyme(ACE) inhibitors, endothelin antagonists, potassium channel agonist/openers, calcium channel blockers, adren-ergic receptor antagonists and nitro vasodilators are assessed.